𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

✍ Scribed by S. SCHNEEWEISS; J. KORZENIK; D. H. SOLOMON; C. CANNING; J. LEE; B. BRESSLER

Book ID
108605661
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
121 KB
Volume
30
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Patient perceptions of the risks and ben
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
✍ Corey A. Siegel; L. Campbell Levy; Todd A. MacKenzie; Bruce E. Sands πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 360 KB πŸ‘ 2 views

Background: For a patient to make informed, preference based decisions, they must be able to balance the risks and benefits of treatment. The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease

Cytokine association with bacterial DNA
Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease
✍ Ana GutiΓ©rrez; RubΓ©n FrancΓ©s; Amparo AmorΓ³s; Pedro Zapater; Marta Garmendia; Moi πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 2 views

## Background: The pathogenesis of inflammatory bowel disease (ibd) involves the interaction between genetic susceptibility, mucosal immunity, and intestinal bacteria. bacterial translocation is a common event in these patients and plays an important role in the perpetuation of chronic intestinal i